苏州纳微科技股份有限公司 简式权益变动报告书 上市公司名称：苏州纳微科技股份有限公司 股票上市地点：上海证券交易所 股票简称：纳微科技 股票代码：688690 信息披露义务人：陈荣华 住所：广东省深圳市福田区******** 通讯地址：广东省深圳市福田区******** 权益变动性质： 减少股份（减持）导致间接持股比例低于5% 签署日期：2025年9月29日 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国证券法》、《上市公 司收购管理办法》、《公开发行证券的公司信息披露内容与格式准则第 15 号- 权益变动报告书》及相关法律、法规和规范性文件编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》及《公开 发行证券的公司信息披露内容与格式准则第 15 号—权益变动报告书》的规定， 本报告书已全面披露信息披露义务人在苏州纳微科技股份有限公司中拥有权益 的股份变动情况。 四、截至本报告书签署之日，除本报告书披露的信息外，信息披露义务人没 有通过任何其他方式 ...

证券代码：688690 证券简称：纳微科技 公告编号：2025-033 苏州纳微科技股份有限公司 关于持股 5%以上股东减持股份至 5%以下 的权益变动提示性公告 股东陈荣华保证向本公司提供的信息真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 本次权益变动为苏州纳微科技股份有限公司（以下简称"公司"）间接 持股 5%股东陈荣华先生减持通过深圳市纳微科技有限公司（以下简称"深圳纳 微"）间接持有的部分公司股份所致，不触及要约收购。 本次权益变动后，信息披露义务人陈荣华先生通过深圳纳微以及苏州纳 合管理咨询有限公司（以下简称"苏州纳合"）间接合计持有公司股份 20,189,661 股，占公司总股本比例为 4.9997%，不再是公司间接持股 5%以上股份 股东。 | 身份证号码 | 440103197004****** | | --- | --- | | 住所 | 广东省深圳市福田区******** | | 是否取得其他国家或地 | 否 | | 区的居留权 | | （二）本次权益变动情况 2025年9月22日至2025年9 ...

Core Viewpoint - Suzhou Nawei Technology Co., Ltd. announced that indirect shareholder Chen Ronghua reduced his stake in the company, dropping below the 5% threshold, which will not affect the company's control or governance [1] Shareholder Changes - Chen Ronghua reduced his holdings by 37,000 shares from September 22 to 29, representing a change of 0.0092% [1] - After this reduction, Chen Ronghua, through Shenzhen Nawei and Suzhou Naha, holds a total of 20,189,661 shares, accounting for 4.9997% of the total share capital [1] - This change does not trigger a mandatory takeover bid and does not lead to changes in the company's controlling shareholder or actual controller [1] Future Plans - The reduction in holdings is part of a previously announced plan, which has not yet been fully executed as of the announcement date [1]

Market Overview - The chemical pharmaceutical sector increased by 0.39% on September 25, with Aosaikang leading the gains [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Top Gainers in Chemical Pharmaceutical Sector - Aosaikang (002755) closed at 23.28, up 10.02% with a trading volume of 126,300 shares and a turnover of 286 million [1] - Guangshengtang (300436) closed at 121.57, up 9.37% with a trading volume of 235,500 shares and a turnover of 2.802 billion [1] - Naimi Technology (688690) closed at 27.99, up 6.02% with a trading volume of 94,700 shares and a turnover of 26.1 million [1] Top Losers in Chemical Pharmaceutical Sector - Mengke Pharmaceutical (688373) closed at 8.61, down 10.96% with a trading volume of 717,800 shares [2] - Borui Pharmaceutical (688166) closed at 66.41, down 8.40% with a trading volume of 239,000 shares [2] - Haichen Pharmaceutical (300584) closed at 57.90, down 5.95% with a trading volume of 103,000 shares [2] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 858 million from institutional investors, while retail investors saw a net inflow of 538 million [2] - The top stocks by net inflow from institutional investors included Guangshengtang with 325 million and Aosaikang with 97.5934 million [3] - Retail investors showed significant interest in Aosaikang, with a net outflow of 66.8017 million [3]

Core Viewpoint - Nanwei Technology experienced a decline of 5.01% on September 23, with a stock price of 25.42 yuan per share and a total market capitalization of 10.265 billion yuan [1] Company Overview - Nanwei Technology, established on October 22, 2007, and listed on June 23, 2021, is located in Suzhou Industrial Park, Jiangsu Province. The company specializes in the research, large-scale production, sales, and application services of high-performance nano microsphere materials [1] - The main business revenue composition includes: 57.62% from chromatography fillers and chromatography media products, 19.72% from chromatography analysis instruments and accessories, 10.44% from liquid chromatography columns and sample pretreatment products, 5.02% from protein chromatography systems and accessories, 3.98% from microsphere products for optoelectronic fields, 1.35% from other products, 1.02% from separation and purification technology services, 0.78% from core microsphere products for IVD, and 0.06% from other supplementary products [1] Fund Holdings - According to data, one fund under Huatai PineBridge holds a significant position in Nanwei Technology. The Huatai PineBridge Science and Technology Innovation Board 2-Year Open Mixed Fund (506006) held 1.0052 million shares in the second quarter, accounting for 1.79% of the fund's net value, ranking as the tenth largest holding [2] - The fund has a current scale of 1.285 billion yuan and has achieved a return of 27.47% year-to-date, ranking 3368 out of 8172 in its category. Over the past year, it has returned 75.98%, ranking 1457 out of 7995, and since inception, it has returned 18.32% [2] Fund Manager Information - The fund manager of Huatai PineBridge Science and Technology Innovation Board 2-Year Open Mixed Fund (506006) is Xia Zheng'an, who has been in the position for 2 years and 343 days. The total asset scale of the fund is 1.418 billion yuan, with the best fund return during the tenure being 35.05% and the worst being 17.35% [3]

Core Viewpoint - Nanwei Technology emphasizes the increasing importance of innovative process research and domestic substitution of key materials in the blood products sector, aligning with the company's strategic focus on chromatography fillers as a core business direction [1] Group 1 - The company has identified blood products as one of the key application directions in its chromatography filler core business strategy, categorized as "3+2" [1] - Nanwei Technology is actively developing new products and application processes to meet customer demands in the blood products market [1] - The company has initiated various R&D projects at different stages to enhance its offerings in the blood products sector [1]

9月8日，纳微科技盘中上涨2.05%，截至13:21，报27.32元/股，成交1.22亿元，换手率1.13%，总市值 110.32亿元。 资金流向方面，主力资金净流出59.88万元，特大单买入108.77万元，占比0.89%，卖出569.31万元，占 比4.66%；大单买入2336.54万元，占比19.13%，卖出1935.88万元，占比15.85%。 纳微科技今年以来股价涨55.78%，近5个交易日跌1.73%，近20日跌0.11%，近60日涨26.77%。 今年以来纳微科技已经1次登上龙虎榜，最近一次登上龙虎榜为2月27日，当日龙虎榜净买入-551.56万 元；买入总计1.04亿元 ，占总成交额比20.37%；卖出总计1.09亿元 ，占总成交额比21.45%。 纳微科技所属申万行业为：医药生物-化学制药-原料药。所属概念板块包括：中盘、新材料、融资融 券、专精特新等。 截至6月30日，纳微科技股东户数1.51万，较上期增加2.29%；人均流通股26739股，较上期减少2.24%。 2025年1月-6月，纳微科技实现营业收入4.14亿元，同比增长21.74%；归母净利润6330.56万元，同比增 长40.5 ...

Group 1 - The company, Nawei Technology, announced plans to hold a collective performance briefing for the biopharmaceutical and CXO industry on September 15, 2025, from 15:00 to 17:00 [1]

Core Points - The company will hold a collective performance briefing for the bioproducts and CXO industry on September 15, 2025, from 15:00 to 17:00 [1][2] - The briefing will be conducted online through the Shanghai Stock Exchange Roadshow Center, allowing for interactive text communication [2][3] - Investors can submit questions in advance from September 8 to September 12, 2025, to be addressed during the event [3] Meeting Details - Meeting Date and Time: September 15, 2025, from 15:00 to 17:00 [2] - Meeting Location: Shanghai Stock Exchange Roadshow Center (https://roadshow.sseinfo.com/) [2] - Meeting Format: Online text interaction [2] Participants - Key attendees include Dr. Jiang Biwang (Chairman), Mr. Zhao Shun (Board Secretary and CFO), Professor Wu Anping (Independent Director), and Ms. Ma Jiahui (Securities Affairs Representative) [2] Investor Participation - Investors can participate online during the meeting and will receive timely responses to their questions [2][3] - Contact information for inquiries includes the Securities Affairs Department, phone: 0512-62956018, and email: ir@nanomicro.com [3]

证券代码：688690 证券简称：纳微科技 公告编号：2025-032 苏州纳微科技股份有限公司 关于召开2025年半年度科创板生物制品及CXO行业 集体业绩说明会的公告 会议召开时间：2025 年 9 月 15 日（星期一）15:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：线上文字互动 投资者可于 2025 年 09 月 08 日（星期一）至 09 月 12 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过投资者关系邮箱 （ir@nanomicro.com）将需要了解和关注的问题提前提供给公司。公司将在文字互 动环节对投资者普遍关注的问题进行回答。 苏州纳微科技股份有限公司（以下简称"公司"）已于 2024 年 8 月 28 日发布 公司 2024 年半年度报告全文及摘要，为便于广大投资者更全面深入地了解公司经 营成果、财务状况，公司计划于 2025 年 09 月 15 日 （星期一） 15:00-17:00 举 行 2025 年半年 ...